Predictive Value of CEA and ctDNA in Lung Cancer Recurrence

NCT07170046 | Not Yet Recruiting

• 1 other identifier: KY2025-310
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

The study aims to investigate the predictive value of CEA levels for postoperative recurrence in the highly sensitive CEA lung cancer patients and to explore whether the dynamic changes of postoperative CEA and MRD in this population are related.This study was carried out to accurately predict the recurrence time, save the time and cost of changing the intervention strategy, and provide more personalized treatment for patients.

Conditions

Lung Carcinoma

Outcome Measures

Primary Outcomes (1)

• Postoperative tumor recurrence or progression

  If the tumor recurs or progresses within 2 years, it will be marked as 1. If not, it will be marked as 0.

  2 years

Study Arms (2)

retrospective cohort

The clinical information of the population in this cohort was retrospectively collected.

prospective cohort

The clinical information of the population in this cohort was prospectively collected.

Eligibility Criteria

• Age: 15 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients from Guangdong Provincial People's Hospital

You may qualify if:

• Preoperative CEA \> 5mg/l
• MRD testing was conducted before the operation
• The primary lesion was resected through surgery
• There should be at least two CEA and MRD follow-up tests within 2 years after the operation
• Postoperative pathology confirmed it as a malignant lung tumor

You may not qualify if:

• Those without available imaging records
• Patients with a history of malignant tumors within the past five years
• Patients with secondary lung cancer

Sponsors & Collaborators

• Guangdong Provincial People's Hospital: lead

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 7, 2025
• First Posted: September 12, 2025
• Study Start: September 15, 2025
• Primary Completion (Estimated): August 1, 2027
• Study Completion (Estimated): August 1, 2027
• Last Updated: September 12, 2025

Record last verified: 2025-04